JP2020528454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528454A5 JP2020528454A5 JP2020524721A JP2020524721A JP2020528454A5 JP 2020528454 A5 JP2020528454 A5 JP 2020528454A5 JP 2020524721 A JP2020524721 A JP 2020524721A JP 2020524721 A JP2020524721 A JP 2020524721A JP 2020528454 A5 JP2020528454 A5 JP 2020528454A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 10
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 claims 7
- 206010042953 Systemic sclerosis Diseases 0.000 claims 7
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 claims 7
- 229960004352 diosmin Drugs 0.000 claims 7
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 claims 7
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims 7
- QAGGICSUEVNSGH-UHFFFAOYSA-N Diosmetin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 QAGGICSUEVNSGH-UHFFFAOYSA-N 0.000 claims 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 6
- MBNGWHIJMBWFHU-UHFFFAOYSA-N diosmetin Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MBNGWHIJMBWFHU-UHFFFAOYSA-N 0.000 claims 6
- 229960001876 diosmetin Drugs 0.000 claims 6
- 235000015428 diosmetin Nutrition 0.000 claims 6
- 230000001363 autoimmune Effects 0.000 claims 5
- 206010040943 Skin Ulcer Diseases 0.000 claims 4
- 208000025865 Ulcer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 231100000397 ulcer Toxicity 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 3
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 208000033471 Cryofibrinogenaemia Diseases 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000002774 Paraproteinemias Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534237P | 2017-07-19 | 2017-07-19 | |
| US62/534,237 | 2017-07-19 | ||
| PCT/US2018/042573 WO2019018455A1 (en) | 2017-07-19 | 2018-07-18 | METHODS OF TREATING AUTOIMMUNE MICROVASCULAR DISORDERS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528454A JP2020528454A (ja) | 2020-09-24 |
| JP2020528454A5 true JP2020528454A5 (https=) | 2021-07-26 |
| JP7237962B2 JP7237962B2 (ja) | 2023-03-13 |
Family
ID=65016682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524721A Active JP7237962B2 (ja) | 2017-07-19 | 2018-07-18 | 自己免疫性微小血管系障害を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11278517B2 (https=) |
| EP (2) | EP3654965B1 (https=) |
| JP (1) | JP7237962B2 (https=) |
| KR (1) | KR102717665B1 (https=) |
| CN (1) | CN111065389B (https=) |
| AU (1) | AU2018304208B2 (https=) |
| CA (1) | CA3069921C (https=) |
| ES (1) | ES2957742T3 (https=) |
| HR (1) | HRP20231517T1 (https=) |
| MX (1) | MX2020000625A (https=) |
| PL (1) | PL3654965T3 (https=) |
| WO (1) | WO2019018455A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306300A (zh) * | 2022-01-04 | 2022-04-12 | 上海交通大学医学院附属仁济医院 | 一种香叶木素的用途及其动物模型的建立方法 |
| WO2026014965A1 (ko) * | 2024-07-11 | 2026-01-15 | 한국 한의학 연구원 | 한련초 추출물 유래 화합물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1288257B1 (it) * | 1996-11-29 | 1998-09-11 | Paoli Ambrosi Gianfranco De | Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico |
| CA2875522A1 (en) * | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Dosage forms and related therapies |
| FR2929276B1 (fr) | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US10596185B2 (en) | 2014-03-31 | 2020-03-24 | Ingredients By Nature | Flavonoid compositions and uses thereof |
-
2018
- 2018-07-18 MX MX2020000625A patent/MX2020000625A/es unknown
- 2018-07-18 EP EP18836058.0A patent/EP3654965B1/en active Active
- 2018-07-18 US US16/632,032 patent/US11278517B2/en active Active
- 2018-07-18 PL PL18836058.0T patent/PL3654965T3/pl unknown
- 2018-07-18 CA CA3069921A patent/CA3069921C/en active Active
- 2018-07-18 KR KR1020207003115A patent/KR102717665B1/ko active Active
- 2018-07-18 ES ES18836058T patent/ES2957742T3/es active Active
- 2018-07-18 EP EP23195481.9A patent/EP4269397A3/en not_active Withdrawn
- 2018-07-18 JP JP2020524721A patent/JP7237962B2/ja active Active
- 2018-07-18 CN CN201880053173.6A patent/CN111065389B/zh active Active
- 2018-07-18 WO PCT/US2018/042573 patent/WO2019018455A1/en not_active Ceased
- 2018-07-18 HR HRP20231517TT patent/HRP20231517T1/hr unknown
- 2018-07-18 AU AU2018304208A patent/AU2018304208B2/en active Active
-
2022
- 2022-02-14 US US17/670,609 patent/US11844777B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Belum et al. | The jarisch–herxheimer reaction: Revisited | |
| Kabins et al. | Anaphylactoid reaction to an initial dose of sodium cephalothin | |
| Hall et al. | Wegener granulomatosis in pediatric patients | |
| ES2745041T3 (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios | |
| Murakami et al. | The value of blocking IL-6 outside of rheumatoid arthritis: current perspective | |
| FR14C0051I2 (fr) | Dialkylfumarates pour le traitement de maladies autoimmunes | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| BR0206160A (pt) | Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos | |
| HRP20241584T1 (hr) | Postupci liječenja sjögrenovog sindroma inhibitorom brutonove tirozin kinaze | |
| JP2020528454A5 (https=) | ||
| BR0307041A (pt) | Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes | |
| MA30665B1 (fr) | Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee. | |
| MA45202A1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| Al-Hasany et al. | Veno-occlusive disease of the liver in Iraq. Nine cases occurring in three Bedouin families | |
| EP1815867A4 (en) | COMBINATION PREPARATION FOR THE TREATMENT OF AUTOIMMUNE DISEASE | |
| Ferguson et al. | Acute mucocutaneous methotrexate toxicity associated with interface dermatitis and numerous eosinophils | |
| Fikri Benbrahim et al. | Treatment with adalimumab in amyloidosis secondary to rheumatoid arthritis: two case reports | |
| MA33455B1 (fr) | Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux | |
| HRP20231517T1 (hr) | Postupci liječenja autoimunih mikrovaskularnih poremećaja | |
| JP2017031144A (ja) | 経口用医薬組成物 | |
| WO2020044114A3 (en) | Methotrexate pharmaceutical composition | |
| Chen et al. | Tocilizumab-induced psoriasis in a patient with rheumatoid arthritis: A case report and literature review | |
| EA202191236A1 (ru) | Местные фармацевтические композиции терифлуномида | |
| Valencia et al. | Schnitzler’s syndrome: A diagnostic crossroads | |
| SU552085A1 (ru) | Средство дл лечени нарушений свертывающей системы крови при тромбоцитопенических состо ни х различного происхождени и дл стимул ции гемоопоэза "эритрофосфатид" |